Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan C Fox

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Circulation. Heart Failure|October 28, 2024
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) SubstudyYousuf Razvi, Daniel P Judge, Ana Martinez-Naharro, et al.
Circulation. Heart Failure|July 2, 2026
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid CardiomyopathyJeffrey M Testani, Daniel P Judge, Barry A Borlaug, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
Journal of the American College of Cardiology|March 12, 2025
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyDaniel P Judge, Kevin M Alexander, Francesco Cappelli, et al.
Circulation|October 10, 2018
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)Carolyn Y Ho, Sharlene M Day, Euan A Ashley, et al.
The New England Journal of Medicine|January 10, 2024
Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology|October 27, 2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CMAhmad Masri, Daniel P Judge, Frederick L Ruberg, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Circulation. Heart Failure|October 28, 2024
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) SubstudyYousuf Razvi, Daniel P Judge, Ana Martinez-Naharro, et al.
Circulation. Heart Failure|July 2, 2026
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid CardiomyopathyJeffrey M Testani, Daniel P Judge, Barry A Borlaug, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
Journal of the American College of Cardiology|March 12, 2025
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyDaniel P Judge, Kevin M Alexander, Francesco Cappelli, et al.
Circulation|October 10, 2018
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)Carolyn Y Ho, Sharlene M Day, Euan A Ashley, et al.
The New England Journal of Medicine|January 10, 2024
Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology|October 27, 2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CMAhmad Masri, Daniel P Judge, Frederick L Ruberg, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
Pageof 4